News

On 14 November 2022, a working group was established at the FGBI "ARRIAH", which was tasked with developing a vaccine against infectious pancreatic necrosis, furunculosis, vibriosis, cold-water vibriosis and winter ulcer disease of salmonids.
The FGBI "ARRIAH" and the FGBU "VGNKI", two leading research centres of the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), are now involved in the development of the vaccine. The vaccine is intended for active immunization of Atlantic salmon and rainbow trout in order to reduce the clinical manifestations and mortality associated with infectious pancreatic necrosis, furunculosis, vibriosis, cold-water vibriosis and winter ulcer disease of salmonids on fish farms.
The inactivated emulsion vaccine against infectious pancreatic necrosis, furunculosis, vibriosis, cold-water vibriosis and winter ulcer disease of salmonids is certainly of considerable interest to business entities of the Russian Federation engaged in salmonid mariculture, is in demand on the Russian market and serves as an example of the implementation of the import substitution strategy.
Currently, the extensive clinical trials of the vaccine against infectious pancreatic necrosis, furunculosis, vibriosis, cold-water vibriosis and winter ulcer disease of salmonids are conducted on a number of fish farms in the Kaluga, Nizhny Novgorod Oblasts and the Republic of Karelia. Clinical trials are an integral stage of veterinary medicinal product development, which precedes its registration and wide practical application. To date, about two million salmonids have been immunized. A total of 5 million fish will be immunized as part of the clinical trials in 2024. The trials are conducted in two target species, namely Atlantic salmon and rainbow trout. During the entire period of the trials, the relevant specialists will daily observe the fish, record death cases, as well as clinical, postmortem and histological signs of diseases and evaluate the safety of the vaccine for susceptible fish populations. These data are an important part of the registration dossier. A veterinary medicinal product that has not passed clinical trials cannot be registered and released to the market. The vaccinated rainbow trout and Atlantic salmon have tolerated the immunization well, no adverse reactions have been observed after the vaccination, the fish eat actively and gain weight well. At the moment, there are two documented favourable reports on the use of the vaccine.